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Their observations during the development of these chioroamide ointments for the
Armed Forces suggested to the present authors that the same type of preparation might
prove useful for protecting the skin against many peace-time irritants and allergens. In
order to test this theory, in April 1944, 12 men highly hypersensitive to poison ivy were
selected by quantitative skin tests performed on 113 Naval volunteers. The relative
protective capacity of 2 different chioroamide-containing ointments, of a blank control
vehicle and of a perborate-containing ointment were compared in controlled experiments
on these 12 subjects. The standardized techniques of the ointment applications and of the
measured exposures to crushed green poison ivy leaves and to the most concentrated poison
ivy extracts obtainable will be described in the detailed report.
The results showed that the relatively non-irritating chloroamide-containing gas pro-
tective ointments of the type of the Army M-5 ointment and the Navy S-330 ointment offer
significant degrees of protection against the poison ivy excitant (fig. 1).
Further studies with ointments of this type appear particularly promising, first, because
some of the preparations have already proved themselves to be quite non-irritating and
non-toxic even when used repeatedly on large skin areas under the most severe conditions
of tropical warfare; and second, because the present studies indicate that the class of
chioroamides used should be capable of rapidly detoxifying many different skin irritants
and sensitizers which are susceptible to inactivation by oxidation and chlorination (e.g.,
certain dyes, dye intermediates, plant derivatives).
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During the past few years a new group of so-called "anti-histaminic" agents has been
developed and studied in Europe (1, 2) and in the United States (3, 4). Among the newer
agents of this type are Benadryl (Parke, Davis and Co.) and Pyribenzamine (Ciba Pharma-
ceutical Co.) •2 The latter drug was introduced and has been extensively investigated in
vitro and in the experimental animal by R. L. Mayer and collaborators (4). Pyribenzamine
is said to possess the desirable properties of very high "anti-histaminic" activity combined
with a relatively low toxicity.
Up to the present we have used Pyribenzamine in a group of 56 dermatologic cases. The
group consisted of 17 cases of urticaria, 11 cases of atopic dermatitis, and 28 cases of pruritus
associated with various dermatoses. The results obtained by us in these three categories
are summarized in tables 1, 2 and 3.
In 13 of the 56 subjects one or more of the following side effects were observed:
Subjeas
Headache 5
Sleepiness 5
'Received for publication March 12, 1946.
Pyribeuzamine (N'-pyridyl-N'-benzyl-N-dimethyl-ethylenediamine monohydrochlo-
ride) is manufactured by the Ciba Pharmaceutical Co., Summit, N. J. who kindly supplied
the material used in this study.
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Nausea 4
Excitement, jitteryness, lightheadedness 3
Urinary frequency 2
Reduction of potency 1
Diplopia 1
Feeling of cold 1
Our patients received Pyribenzamine in doses of from 50mg. to 300mg. in each 24 hrs.,
over periods varying from a few days to several months. There was no evidence that the
TABLE 1
17 Ca8es of urticaiia (mci. giaiU urticaria)
ACUTE URTICARIA
(or LESS THAN 4
WEEKS' DURATION)
SUBACUTE URTICARIA
(op LESS THAN 3
MONTHS' DURATION)
CHRONIC ORTICARIA
(oP MORE THAN 3
MONTHS' DURATION)
TOTAL
Total no. of cases 5 2 10 17
Cases with good to excellent
relief* from Pyribenzamine
alone 2 — 5 7
Cases with fair relief5 from
Pyribenzamine alone
Cases with fair to excellent
— 1 1 2
relief5 from Pyribenzamine
combined with other therapy.
Cases with no relief5
1
2
1
—
1
1
3
3
Insufficient data for evaluation. — — 2 2
* "Relief" refers to significant reduction of number of urticarial lesions, significant
reduction of swelling and significant reduction of itching.
TABLE 2
11 Czse of atopic dermatitis
Total no. of cases U
Cases with good to excellent relief5 from Pyribenzamine alone
Cases with fair relief5 from Pyribenzamine alone 0
Cases with fair to excellent relief5 from Pyribenzamine combined with other therapy. 5
Cases with no relief5
Insufficient data for evaluation —
* "Relief" refers to significant improvement of eruption and lessening of itching.
t This patient obtained complete relief also from long standing asthma due primarily
to exposure to dog dander.
incidence of undesirable effects increased with prolonged administration. On the contrary,
the greater number of side effects occurred within the first few days of administration. In
2 cases we were obliged to discontinue the drug because of the undesirable side-effects.
No drug eruptions and no visceral damage appeared in our cases. Pyribenzamine did not
produce pathologic changes in the hematopoetic or urinary system as detectable by blood
counts and urine examinations. These examinations were carried out on all our patients
at weekly intervals. Despite these negative findings we believe that for the present all
patients using this new class of drugs should be kept under close methcal control with
laboratory studies at regular intervals during the entire period of use.
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COMMENT
Pyribenzamine appeared to be of therapeutic value in controlling the eruption and the
itching in about one-half the cases of urticaria treated. It is noteworthy that 5 of 10 cases
of long standing and ordinarily intractable urticaria experienced rapid and great benefits
from the drug.
Pyribenzamine could not be shown to be of value in controlling the eruption and the
itching in most cases of atopic dermatitis. However, in one case of the 11 treated, Pyri-
benzamine was of proven and significant benefit.
Pyribenzamine appeared to be of significant therapeutic value in some cases of "essen-
tial" pruritus and pruritus associated with various dermatoses.
TABLE 3
28 Case$ of pruritus associated with miscellan eous dermatoses
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Totalno.ofcases
Cases with good to ex-
cellent relief* from
Pyribenzamine alone.
Cases with fair relief*
from Pyribenzamine
alone
Cases with fair to ex-
cellent relief* from
Pyribensamine com-
bined with other
therapy
Cases with no relief*...
Insufficient data for
evaluation
3
2
—
1
—
5
1
1
1
2
1
—
1
3
—
3
1
—
1
2
—
1
1 2 1
—
1
2
2
1
* "Relief" refers to significant reduction of itching.
No serious side-effects were observed. The minor discomforts which occurred did not
in general interfere with the continued administration of Pyribenzamine. Despite these
negative findings we believe that regular medical and laboratory examinations should be
carried out on all patients using this new class of drugs over long periods.
In one case of chronic urticaria and in one case of chronic asthma associated with atopic
dermatitis, there was evidence which suggested that in some cases the temporary adminis-
tration of Pyribenzamine may lead to a relatively long-lasting cessation of symptoms and to
a reduction of clinical sensitivity which persists for a significant time without further use
of the drug.
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In 1942 Joliffe, Rosenbium and Sawhill reported (N. Joliffe, L. A. Rosenbium
and J. Sawhill: the effects of pyridoxine (vitamin B6) on resistant adolescent
acne, Jour. Investigative Derm., 5, 143, 1942) the benefit they obtained in the
treatment of acne vulgaris by administering B6 in large doses over a long period.
In their first series of 10 cases, 3 were cured, one in 5 months, one in 10 and one in
11 months. All the others improved; but in 4 whose eruption did not recur when
the vitamin was discontinued they suspected that the improvement was not due
to its influence.
Their second series consisted of 40 students, 11 of whom became free of the
eruption while on.treatment with pyridoxine. One was clear after only 1 month
of treatment, 1 after 3 months and the others after an unstated period of treat-
ment with B6 in doses ranging from 50 to 250 mg. per day. Of this group 19
improved, 6 were not beneflitted. Of 35 controls treated with a placebo tablet
resembling in appearance the one containing the pyridoxine, 7 improved but none
were entirely freed from the eruption.
In an effort to duplicate their results, I have treated 41 cases of acne vulgaris,
18 in young individuals normal in health except for the acne, 23 in patients with
pulmonary tuberculosis, inmates of a sanitarium. Eleven cases have been
excluded because they quit the treatment before the third month, which seemed
to me a reasonable minimum. Three others are omitted because of complications
which made it impossible to judge the effect of the medication. All patients
received local treatment, a sulfur lotion or cream for the area involved and in
many cases a sulfur or chioral hydrate scalp stimulant.
Nineteen cases who received 50 mg. of vitamin B6 daily for from 3 to 8 months
failed to show improvement that could be ascribed to the vitamin.
In a few cases the dosage was increased. A man 30 years old was given 50 mg.
daily for 8 months, then 100 mg. a day for 2 months without definite benefit.
A man of 32 was given 50 mg. per day for 9 months, then 200 mg. a day for
another month without benefit.
A boy of 16 was given 50 mg. daily for 6 months, 150 mg. a day for another
month, then 225 mg. daily for 2 months more without improvement.
